NU Hospital Group-Vaestra Goetalandsregionen
- Address
- Larketorpsvagen
Sponsor Overview
Specializations
Type 1 Diabetes
Clinical research activity is centred on type 1 diabetes, with attention to newly diagnosed patients and the preservation of residual insulin secretion. The funded trial addresses immune-mediated disease processes in early diabetes and the clinical course of beta-cell function.
- Newly diagnosed type 1 diabetes
- Residual insulin secretion
- Beta-cell function
Interest in this area reflects a focus on metabolic and immunologic aspects of diabetes care within a hospital-based research setting.
Endocrinology and Metabolic Disease
The sponsor's research landscape includes endocrinology and metabolic disease, with emphasis on glucose regulation and the physiological changes associated with autoimmune diabetes. Clinical interest extends to biomarkers of pancreatic function and disease progression.
- Glucose homeostasis
- Pancreatic function
- Autoimmune diabetes
These topics align with a care environment that supports disease monitoring and the evaluation of endocrine outcomes.
Immunology
Research activity also involves immunology, particularly the immune mechanisms underlying type 1 diabetes. The study focus suggests interest in inflammatory pathways and immune modulation in the context of early disease.
- Immune-mediated disease
- Inflammatory pathways
- Immune modulation
This area connects clinical diabetes management with investigation of immune-related therapeutic targets.
Clinical Biomarkers
The sponsor is engaged in the assessment of clinical biomarkers relevant to diabetes progression, including measures of stimulated C-peptide response. Such endpoints are used to track pancreatic activity and treatment-related changes in early-stage disease.
- C-peptide
- Stimulated secretion markers
- Metabolic endpoints
These biomarker-focused interests support research into disease preservation and functional assessment in diabetes.
Hospital-Based Therapeutic Research
As a hospital-based sponsor, the organisation supports therapeutic research in a clinical care setting, with activity concentrated in a single ongoing study and collaboration across multiple research sites. The therapeutic domain is focused on interventions relevant to autoimmune diabetes and early disease management.
- Hospital clinical research
- Autoimmune disease intervention
- Multi-site collaboration
The research portfolio is directed toward treatment-related questions in diabetes care within the healthcare system.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Ixekizumab on Endogenous Insulin Preservation in Newly Diagnosed Type 1 Diabetes: A Randomized, Placebo-Controlled Trial |  Sweden | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 16 sites across their trial portfolio.
Therapeutic Focus
- 1.Hormonal diseases1 trial89 other sponsors
Partnered Research Centres
16 centres- Address
- Dag Hammarskjolds Vag 10b, Uppsala Domkyrkofors., 752 37 Uppsala
- Address
- Larketorpsvagen, 461 85 Trollhättan
- Address
- Behandlingsvagen 7, Harlanda, 416 50 Gothenburg
- Address
- Vasagatan 27, Falu Kristine, 791 37 Falun
- Address
- Lasarettsvagen 1, 302 33 Varberg
- Address
- Lanssjukhuset Ryhov, Sjukhusgatan, 553 05 Jönköping
Want to get in touch with this sponsor?
Send a question and we'll pass it on to NU Hospital Group-Vaestra Goetalandsregionen.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.